|
1
|
Dahia PL: Pheochromocytoma and
paraganglioma pathogenesis: Learning from genetic heterogeneity.
Nat Rev Cancer. 14:108–119. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lenders JW, Eisenhofer G, Mannelli M and
Pacak K: Phaeochromocytoma. Lancet. 366:665–675. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lam AK: Update on adrenal tumours in 2017
world health organization (WHO) of endocrine tumours. Endocr
Pathol. 28:213–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lloyd RV, Osamura RY, Klöppel G and Rosai
J: WHO Classification of Tumours of Endocrine Organs. 4th. IACR;
Lyon: 2017
|
|
5
|
Roman-Gonzalez A and Jimenez C: Malignant
pheochromocytoma-paraganglioma: Pathogenesis, TNM staging and
current clinical trials. Curr Opin Endocrinol Diabetes Obes.
24:174–183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amin B, Edge S and Greene F: AJCC cancer
staging manual. Springer; New York: 2017, View Article : Google Scholar
|
|
7
|
Lenders JW, Duh QY, Eisenhofer G,
Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K and
Young WF Jr; Endocrine Society, : Pheochromocytoma and
paraganglioma: An endocrine society clinical practice guideline. J
Clin Endocrinol Metab. 99:1915–1942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crona J, Taïeb D and Pacak K: New
perspectives on pheochromocytoma and paraganglioma: Towards a
molecular classification. Endocr Rev. 38:489–515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pacak K and Del Rivero J: Pheochromocytoma
(Updated June 10, 2013) = Endotext. De Groot LJ, Chrousos G, Dungan
K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M,
McLachlan R, New M, et al: MDText.com, Inc.; South Dartmouth, MA:
2000
|
|
10
|
Neumann HP, Bausch B, McWhinney SR, Bender
BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K,
et al: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl
J Med. 346:1459–1466. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pacak K and Wimalawansa SJ:
Pheochromocytoma and paraganglioma. Endocr Pract. 21:406–412. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin Y, Yao L, King EE, Buddavarapu K,
Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F,
et al: Germline mutations in TMEM127 confer susceptibility to
pheochromocytoma. Nat Genet. 42:229–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsirlin A, Oo Y, Sharma R, Kansara A,
Gliwa A and Banerji MA: Pheochromocytoma: A review. Maturitas.
77:229–238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baysal BE, Ferrell RE, Willett-Brozick JE,
Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE,
Rubinstein WS, Myers EN, et al: Mutations in SDHD, a mitochondrial
complex II gene, in hereditary paraganglioma. Science. 287:848–851.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Niemann S and Müller U: Mutations in SDHC
cause autosomal dominant paraganglioma, type 3. Nat Genet.
26:268–270. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Astuti D, Latif F, Dallol A, Dahia PL,
Douglas F, George E, Sköldberg F, Husebye ES, Eng C and Maher ER:
Gene mutations in the succinate dehydrogenase subunit SDHB cause
susceptibility to familial pheochromocytoma and to familial
paraganglioma. Am J Hum Genet. 69:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karasek D, Shah U, Frysak Z, Stratakis C
and Pacak K: An update on the genetics of pheochromocytoma. J Hum
Hypertens. 27:141–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brouwers FM, Eisenhofer G, Tao JJ, Kant
JA, Adams KT, Linehan WM and Pacak K: High frequency of SDHB
germline mutations in patients with malignant
catecholamine-producing paragangliomas: Implications for genetic
testing. J Clin Endocrinol Metab. 91:4505–4509. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fishbein L, Leshchiner I, Walter V,
Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA,
Ghayee HK, Else T, Ling S, et al: Comprehensive molecular
characterization of pheochromocytoma and paraganglioma. Cancer
Cell. 31:181–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
NGS, in PPGL (NGSnPPGL) Study Group, ;
Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, Welander J,
Tops CM, Firth H, Dwight T, et al: Consensus statement on
next-generation-sequencing-based diagnostic testing of hereditary
phaeochromocytomas and paragangliomas. Nat Rev Endocrinol.
13:233–247. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zelinka T and Widimský J:
Pheochromocytoma-why is its early diagnosis so important for
patient? Vnitr Lek. 61:487–491. 2015.PubMed/NCBI
|
|
22
|
Pacak K, Linehan WM, Eisenhofer G, Walther
MM and Goldstein DS: Recent advances in genetics, diagnosis,
localization and treatment of pheochromocytoma. Ann Intern Med.
134:315–329. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen H, Sippel RS, O'Dorisio MS, Vinik AI,
Lloyd RV and Pacak K; North American Neuroendocrine Tumor Society
(NANETS), : The North American neuroendocrine tumor society
consensus guideline for the diagnosis and management of
neuroendocrine tumors: Pheochromocytoma, paraganglioma and
medullary thyroid cancer. Pancreas. 39:775–783. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lenders JW, Pacak K, Walther MM, Linehan
WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS and Eisenhofer
G: Biochemical diagnosis of pheochromocytoma: Which test is best?
JAMA. 287:1427–1434. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhofer G, Siegert G, Kotzerke J,
Bornstein SR and Pacak K: Current progress and future challenges in
the biochemical diagnosis and treatment of pheochromocytomas and
paragangliomas. Horm Metab Res. 40:329–337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eisenhofer G, Goldstein DS, Walther MM,
Friberg P, Lenders JW, Keiser HR and Pacak K: Biochemical diagnosis
of pheochromocytoma: How to distinguish true-from false-positive
test results. J Clin Endocrinol Metab. 88:2656–2666. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jacques AE, Sahdev A, Sandrasagara M,
Goldstein R, Berney D, Rockall AG, Chew S and Reznek RH: Adrenal
phaeochromocytoma: Correlation of MRI appearances with histology
and function. Eur Radiol. 18:2885–2892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Motta-Ramirez GA, Remer EM, Herts BR, Gill
IS and Hamrahian AH: Comparison of CT Findings in symptomatic and
incidentally discovered pheochromocytomas. Am J Roentgenol.
185:684–688. 2005. View Article : Google Scholar
|
|
29
|
Čtvrtlík F, Heřman M, Študent V, Tichá V
and Minařík J: Differential diagnosis of incidentally detected
adrenal masses revealed on routine abdominal CT. Eur J Radiol.
69:243–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patel J, Davenport MS, Cohan RH and Caoili
EM: Can established CT attenuation and washout criteria for adrenal
adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol.
201:122–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schieda N, Alrashed A, Flood TA, Samji K,
Shabana W and McInnes MD: Comparison of quantitative MRI and CT
washout analysis for differentiation of adrenal pheochromocytoma
from adrenal adenoma. AJR Am J Roentgenol. 206:1141–1148. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang GM, Shi B, Sun H, Jin ZY and Xue HD:
Differentiating pheochromocytoma from lipid-poor adrenocortical
adenoma by CT texture analysis: Feasibility study. Abdom Radiol.
42:2305–2313. 2017. View Article : Google Scholar
|
|
33
|
McDermott S, McCarthy CJ and Blake MA:
Images of pheochromocytoma in adrenal glands. Gland Surg.
4:350–358. 2015.PubMed/NCBI
|
|
34
|
Pacak K, Goldstein DS, Doppman JL, Shulkin
BL, Udelsman R and Eisenhofer G: A ‘pheo’ lurks: Novel approaches
for locating occult pheochromocytoma. J Clin Endocrinol Metab.
86:3641–3646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Korobkin M, Giordano TJ, Brodeur FJ,
Francis IR, Siegelman ES, Quint LE, Dunnick NR, Heiken JP and Wang
HH: Adrenal adenomas: Relationship between histologic lipid and CT
and MR findings. Radiology. 200:743–747. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Remer EM, Motta-Ramirez GA, Shepardson LB,
Hamrahian AH and Herts BR: CT histogram analysis in pathologically
proven adrenal masses. Am J Roentgenol. 187:191–196. 2006.
View Article : Google Scholar
|
|
37
|
Lubner MG, Smith AD, Sandrasegaran K,
Sahani DV and Pickhardt PJ: CT texture analysis: Definitions,
applications, biologic correlates and challenges. RadioGraphics.
37:1483–1503. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Northcutt BG, Raman SP, Long C, Oshmyansky
AR, Siegelman SS, Fishman EK and Johnson PT: MDCT of adrenal
masses: Can dual-phase enhancement patterns be used to
differentiate adenoma and pheochromocytoma? AJR Am J Roentgenol.
201:834–839. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Korobkin M, Brodeur FJ, Yutzy GG, Francis
IR, Quint LE, Dunnick NR and Kazerooni EA: Differentiation of
adrenal adenomas from nonadenomas using CT attenuation values. AJR
Am J Roentgenol. 166:531–536. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Caoili EM, Korobkin M, Francis IR, Cohan
RH and Dunnick NR: Delayed enhanced CT of lipid-poor adrenal
adenomas. AJR Am J Roentgenol. 175:1411–1415. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Szolar DH, Korobkin M, Reittner P,
Berghold A, Bauernhofer T, Trummer H, Schoellnast H, Preidler KW
and Samonigg H: Adrenocortical carcinomas and adrenal
pheochromocytomas: Mass and enhancement loss evaluation at delayed
contrast-enhanced CT. Radiology. 234:479–485. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kumagae Y, Fukukura Y, Takumi K, Shindo T,
Tateyama A, Kamiyama T, Kamimura K and Nakajo M: Distinguishing
adrenal adenomas from non-adenomas on dynamic enhanced CT: A
comparison of 5 and 10 min delays after intravenous contrast medium
injection. Clin Radiol. 68:696–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mukherjee JJ, Peppercorn PD, Reznek RH,
Patel V, Kaltsas G, Besser M and Grossman AB: Pheochromocytoma:
Effect of nonionic contrast medium in CT on circulating
catecholamine levels. Radiology. 202:227–231. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bessell-Browne R and O'Malley ME: CT of
pheochromocytoma and paraganglioma: Risk of adverse events with
i.v. administration of nonionic contrast material. AJR Am J
Roentgenol. 188:970–974. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mansmann G, Lau J, Balk E, Rothberg M,
Miyachi Y and Bornstein SR: The clinically inapparent adrenal mass:
Update in diagnosis and management. Endocr Rev. 25:309–340. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tsushima Y, Takahashi-Taketomi A and Endo
K: Diagnostic utility of diffusion-weighted MR imaging and apparent
diffusion coefficient value for the diagnosis of adrenal tumors. J
Magn Reson Imaging. 29:112–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Umanodan T, Fukukura Y, Kumagae Y, Shindo
T, Nakajo M, Takumi K, Nakajo M, Hakamada H, Umanodan A and
Yoshiura T: ADC histogram analysis for adrenal tumor histogram
analysis of apparent diffusion coefficient in differentiating
adrenal adenoma from pheochromocytoma. J Magn Reson Imaging.
45:1195–1203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dong Y and Liu Q: Differentiation of
malignant from benign pheochromocytomas with diffusion-weighted and
dynamic contrast-enhanced magnetic resonance at 3.0 T. J Comput
Assist Tomogr. 36:361–366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim S, Salibi N, Hardie AD, Xu J, Lim RP,
Lee VS and Taouli B: Characterization of adrenal pheochromocytoma
using respiratory-triggered proton MR spectroscopy: Initial
experience. AJR Am J Roentgenol. 192:450–454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Melo HJ, Goldman SM, Szejnfeld J, Faria
JF, Huayllas MK, Andreoni C and Kater CE: Application of a protocol
for magnetic resonance spectroscopy of adrenal glands: An
experiment with over 100 cases. Radiol Bras. 47:333–341. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Reimer P, Parizel PM and Stichnoth FA:
Clinical MR imaging: A practical approach Second, completely
revised and updated. Springer-Verlag; Berlin Heidelberg New York:
2006, View Article : Google Scholar
|
|
52
|
Shellock FG and Kanal E: Safety of
magnetic resonance imaging contrast agents. J Magn Reson Imaging.
10:477–484. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Taïeb D, Timmers HJ, Hindié E, Guillet BA,
Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC and de
Krijger RR: EANM 2012 guidelines for radionuclide imaging of
phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging.
39:1977–1995. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bombardieri E, Giammarile F, Aktolun C,
Baum RP, Bischof Delaloye A, Maffioli L, Moncayo R, Mortelmans L,
Pepe G, Reske SN, et al: 131I/123I-metaiodobenzylguanidine (mIBG)
scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl
Med Mol Imaging. 37:2436–2446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Treglia G, Cocciolillo F, de Waure C, Di
Nardo F, Gualano MR, Castaldi P, Rufini V and Giordano A:
Diagnostic performance of 18F-dihydroxyphenylalanine positron
emission tomography in patients with paraganglioma: A
meta-analysis. Eur J Nucl Med Mol Imaging. 39:1144–1153. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fiebrich HB, Brouwers AH, Kerstens MN,
Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van
der Wal JE, et al: 6-(F-18)Fluoro-l-dihydroxyphenylalanine positron
emission tomography is superior to conventional imaging with
123I-metaiodobenzylguanidine scintigraphy, computer tomography and
magnetic resonance imaging in localizing tumors causing
catecholamine excess. J Clin Endocrinol Metab. 94:3922–3930. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Timmers HJ, Chen CC, Carrasquillo JA,
Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams
KT and Pacak K: Staging and functional characterization of
pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography. J Natl Cancer
Inst. 104:700–708. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Janssen I, Chen CC, Millo CM, Ling A,
Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, et al:
PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and
in comparison with CT/MRI for the localization of sporadic
metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol
Imaging. 43:1784–1791. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jing H, Li F, Wang L, Wang Z, Li W, Huo L
and Zhang J: Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT and
MIBG SPECT/CT in the evaluation of suspected primary
pheochromocytomas and paragangliomas. Clin Nucl Med. 42:525–529.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chang CA, Pattison DA, Tothill RW, Kong G,
Akhurst TJ, Hicks RJ and Hofman MS: 68Ga-DOTATATE and
18F-FDG PET/CT in paraganglioma and pheochromocytoma:
Utility, patterns and heterogeneity. Cancer Imaging. 16:2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tato A, Orte L, Diz P, Quereda C and
Ortuno J: Malignant pheochromocytoma, still a therapeutic
challenge. Am J Hypertens. 10:479–481. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Strong VE, Kennedy T, Al-Ahmadie H, Tang
L, Coleman J, Fong Y, Brennan M and Ghossein RA: Prognostic
indicators of malignancy in adrenal pheochromocytomas: Clinical,
histopathologic and cell cycle/apoptosis gene expression analysis.
Surgery. 143:759–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Thompson LD: Pheochromocytoma of the
adrenal gland scaled score (PASS) to separate benign from malignant
neoplasms: A clinicopathologic and immunophenotypic study of 100
cases. Am J Surg Pathol. 26:551–566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mlika M, Kourda N, Zorgati MM, Bahri S,
Ben Ammar S and Zermani R: Prognostic value of Pheochromocytoma of
the adrenal gland scaled score (Pass score) tests to separate
benign from malignant neoplasms. Tunis Med. 91:209–215.
2013.PubMed/NCBI
|
|
65
|
de Wailly P, Oragano L, Radé F, Beaulieu
A, Arnault V, Levillain P and Kraimps JL: Malignant
pheochromocytoma: New malignancy criteria. Langenbecks Arch Surg.
397:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Duregon E, Volante M, Bollito E, Goia M,
Buttigliero C, Zaggia B, Berruti A, Scagliotti GV and Papotti M:
Pitfalls in the diagnosis of adrenocortical tumors: A lesson from
300 consultation cases. Hum Pathol. 46:1799–1807. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ctvrtlik F, Koranda P and Tichy T: Adrenal
disease: A clinical update and overview of imaging. Biomed Pap Med
Fac Univ Palacky Olomouc Czech Repub. 158:23–34. 2014.PubMed/NCBI
|
|
68
|
Hodin R, Lubitz C, Phitayakorn R and
Stephen A: Diagnosis and management of pheochromocytoma. Curr Probl
Surg. 51:151–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Vanderveen KA, Thompson SM, Callstrom MR,
Young WF Jr, Grant CS, Farley DR, Richards ML and Thompson GB:
Biopsy of pheochromocytomas and paragangliomas: Potential for
disaster. Surgery. 146:1158–1166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Brunaud L, Nguyen-Thi PL, Mirallie E,
Raffaelli M, Vriens M, Theveniaud PE, Boutami M, Finnerty BM,
Vorselaars WM, Rinkes IB, et al: Predictive factors for
postoperative morbidity after laparoscopic adrenalectomy for
pheochromocytoma: A multicenter retrospective analysis in 225
patients. Surg Endosc. 30:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Perel Y, Schlumberger M, Marguerite G,
Alos N, Revillon Y, Sommelet D, De Lumley L, Flamant F, Dyon JF,
Lutz P, et al: Pheochromocytoma and paraganglioma in children: A
report of 24 cases of the french society of pediatric oncology.
Pediatr Hematol Oncol. 14:413–422. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang W, Li P, Wang Y, Wang Y, Ma Z, Wang
G, Gao J and Zhou H: Effectiveness and safety of laparoscopic
adrenalectomy of large pheochromocytoma: A prospective,
nonrandomized, controlled study. Am J Surg. 210:230–235. 2015.
View Article : Google Scholar : PubMed/NCBI
|
